Response heterogeneity as a new biomarker of treatment response in patients with neuroendocrine tumors

References

• Oronsky B , MaPC, MorgenszternD, CarterCA. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia19(12), 991–1002 (2017).
   PubMed Web of Science ®Google Scholar
• Rindi G , MeteO, UccellaSet al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol33(1), 115–154 (2022).
   PubMed Web of Science ®Google Scholar
• Metz DC , JensenRT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology135(5), 1469–1492 (2008).
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R , CapdevilaJ, Crespo-HerreroGet al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol21(9), 1794–1803 (2010).
   PubMed Web of Science ®Google Scholar
• Cives M , StrosbergJR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin68(6), 471–487 (2018).
   PubMed Web of Science ®Google Scholar
• Raymond E , García-CarboneroR, WiedenmannB, GrandeE, PavelM. Systemic therapeutic strategies for GEP-NETS: what can we expect in the future?Cancer Metastasis Rev33(1), 367–372 (2014).
   PubMed Web of Science ®Google Scholar
• Narayanan S , KunzPL. Role of somatostatin analogues in the treatment of neuroendocrine tumors. Hematol Oncol Clin North Am30(1), 163–177 (2016).
   PubMed Web of Science ®Google Scholar
• Khan MS , PritchardDM. Neuroendocrine tumours: what gastroenterologists need to know. Frontline Gastroenterology13(1), 50 (2022).
   PubMed Web of Science ®Google Scholar
• Raj N , FazioN, StrosbergJ. Biology and systemic treatment of advanced gastroenteropancreatic neuroendocrine tumors. American Society of Clinical Oncology Educational Book38, 292–299doi:10.1200/EDBK_200893 (2018).
   PubMedGoogle Scholar
• Roviello G , ZanottiL, VenturiniS, BottiniA, GeneraliD. Role of targeted agents in neuroendocrine tumors: results from a meta-analysis. Cancer Biol Ther17(9), 883–888 (2016).
   PubMed Web of Science ®Google Scholar
• Uri I , Grozinsky-GlasbergS. Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Clin Diabetes Endocrinol4, 16 (2018).
   PubMedGoogle Scholar
• Chan DL , ClarkeSJ, DiakosCIet al. Prognostic and predictive biomarkers in neuroendocrine tumours. Crit Rev Oncol Hematol113, 268–282 (2017).
   PubMed Web of Science ®Google Scholar
• Therasse P , ArbuckSG, EisenhauerEAet al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst92(3), 205–216 (2000).
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA , TherasseP, BogaertsJet al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer45(2), 228–247 (2009).
   PubMed Web of Science ®Google Scholar
• Vullierme MP , RuszniewskiP, de MestierL. Are recist criteria adequate in assessing the response to therapy in metastatic NEN?Rev Endocr Metab Disord22, 637–645 (2021).
   PubMed Web of Science ®Google Scholar
• van Treijen MJC , SchoeversJMH, HeeresBCet al. Defining disease status in gastroenteropancreatic neuroendocrine tumors: Choi-criteria or RECIST? Abdominal Radiology 47(3), 1071–1081 (2022).
   PubMed Web of Science ®Google Scholar
• Cives M , PelleE, StrosbergJ. Emerging treatment options for gastroenteropancreatic neuroendocrine tumors. J Clin Med9(11), 3655 (2020).
   PubMed Web of Science ®Google Scholar
• Cives M , SoaresHP, StrosbergJ. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. Curr Opin Oncol28(4), 359–366 (2016).
   PubMed Web of Science ®Google Scholar
• Gatta R , DepeursingeA, RatibO, MichielinO, LeimgruberA. Integrating radiomics into holomics for personalised oncology: from algorithms to bedside. Eur Radiol Exp4(1), 11 (2020).
   PubMedGoogle Scholar
• Govind D , JenKY, MatsukumaKet al. Improving the accuracy of gastrointestinal neuroendocrine tumor grading with deep learning. Sci Rep10(1), DOI: 10.1038/s41598-020-67880-z (2020).
   Web of Science ®Google Scholar
• Luo Y-J , ChenX, ChenJet al. Preoperative prediction of pancreatic neuroendocrine neoplasms grading based on enhanced computed tomography imaging: validation of deep learning with a convolutional neural network. Neuroendocrinology110, 338–350 (2019).
   PubMed Web of Science ®Google Scholar
• Gao X , WangX. Deep learning for World Health Organization grades of pancreatic neuroendocrine tumors on contrast-enhanced magnetic resonance images: a preliminary study. Int J Comput Assist Radiol Surg14(11), 1981–1991 (2019).
   PubMed Web of Science ®Google Scholar
• Caplin ME , PavelM, ĆwikłaJBet al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med371(3), 224–233 (2014).
   PubMed Web of Science ®Google Scholar
• Pavel M , DromainC, RonotMet al. The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumors. Future Oncology (2023).
   Web of Science ®Google Scholar
• Huyge V , GarciaC, AlexiouJet al. Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients. Clin Oncol (R Coll Radiol)22(10), 818–827 (2010).
   PubMed Web of Science ®Google Scholar
• Humbert O , ChardinD. Dissociated response in metastatic cancer: an atypical pattern brought into the spotlight with immunotherapy. Front Oncol10, DOI: 10.3389/fonc.2020.566297 (2020).
   PubMed Web of Science ®Google Scholar
• Parast L , CaiT, TianL. Evaluating surrogate marker information using censored data. Stat Med36(11), 1767–1782 (2017).
   PubMed Web of Science ®Google Scholar
• Wang X , ParastL, TianLU, CaiT. Model-free approach to quantifying the proportion of treatment effect explained by a surrogate marker. Biometrika107(1), 107–122 (2020).
   PubMed Web of Science ®Google Scholar
• Wang Y , TaylorJM. A measure of the proportion of treatment effect explained by a surrogate marker. Biometrics58(4), 803–812 (2002).
   PubMed Web of Science ®Google Scholar
• Dong ZY , ZhaiHR, HouQYet al. Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer. Oncologist22(1), 61–69 (2017).
   PubMed Web of Science ®Google Scholar
• Vitale I , ShemaE, LoiS, GalluzziL. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat Med27(2), 212–224 (2021).
   PubMed Web of Science ®Google Scholar
• Chou WC , ChenJS, HungYSet al. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors. Anticancer Res.34(10), 5661–5669 (2014).
   PubMed Web of Science ®Google Scholar
• Kim M , LeeS, LeeJet al. The role of plasma chromogranin A as assessment of treatment response in non-functioning gastroenteropancreatic neuroendocrine tumors. Cancer Res Treat48(1), 153 (2016).
   PubMed Web of Science ®Google Scholar
• Gut P , CzarnywojtekA, FischbachJet al. Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls. Arch Med Sci12(1), 1–9 (2016).
   PubMed Web of Science ®Google Scholar
• Dromain C , PavelME, RuszniewskiPet al. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors. BMC Cancer19(1), 66 (2019).
   PubMedGoogle Scholar
• Tazdait M , MezquitaL, LahmarJet al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer88, 38–47 (2018).
   PubMed Web of Science ®Google Scholar
• Hendlisz A , DeleporteA, DelaunoitTet al. The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer. PLOS ONE10(9), e0138341 (2015).
   PubMed Web of Science ®Google Scholar
• Carlino MS , SaundersCA, HayduLEet al. (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. Eur J Cancer49(2), 395–402 (2013).
   PubMed Web of Science ®Google Scholar
• Woff E , HendliszA, GarciaCet al. Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer. Eur J Nucl Med Mol Imaging43(10), 1792–1801 (2016).
   PubMed Web of Science ®Google Scholar
• Puranik AD , DromainC, FleshnerNet al. Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer. Cancers (Basel)13(14), 3607 (2021).
   PubMed Web of Science ®Google Scholar
• Wang L , TangK, ZhangQet al. Somatostatin Receptor-Based Molecular Imaging and Therapy for Neuroendocrine Tumors. Biomed Res Int2013, DOI: 10.1155/2013/102819 (2013).
   Web of Science ®Google Scholar
• Önner H , AbdülrezzakÜ, TutuşA. Could the skewness and kurtosis texture parameters of lesions obtained from pretreatment Ga-68 DOTA-TATE PET/CT images predict receptor radionuclide therapy response in patients with gastroenteropancreatic neuroendocrine tumors?Nucl Med Commun41(10), 1034–1039 (2020).
   PubMed Web of Science ®Google Scholar
• Boudreaux JP , KlimstraDS, HassanMMet al. The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas39(6), 753–766 (2010).
   PubMed Web of Science ®Google Scholar
• Kunz PL , Reidy-LagunesD, AnthonyLBet al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas42(4), 557–577 (2013).
   PubMed Web of Science ®Google Scholar
• Dasari A , ShenC, HalperinDet al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol3(10), 1335–1342 (2017).
   PubMed Web of Science ®Google Scholar